345 related articles for article (PubMed ID: 15935302)
21. Predicting renal graft failure by sCD30 levels and de novo HLA antibodies at 1year post-transplantation.
Wang D; Wu G; Chen J; Yu Z; Wu W; Yang S; Tan J
Transpl Immunol; 2012 Jun; 26(4):235-9. PubMed ID: 22446727
[TBL] [Abstract][Full Text] [Related]
22. Pretransplant soluble CD30 is a better predictor of posttransplant development of donor-specific antibodies and acute vascular rejection than panel reactive antibodies.
Vaidya S; Partlow D; Barnes T; Gugliuzza K
Transplantation; 2006 Dec; 82(12):1606-9. PubMed ID: 17198244
[TBL] [Abstract][Full Text] [Related]
23. HLA antibodies and soluble CD30 are associated with poor renal graft outcome: updated results of a single-center cross-sectional study.
Langan LL; D'Orsogna L; Park LP; Hughes TL; Irish A; Luxton G; Witt CS; Christiansen FT
Clin Transpl; 2006; ():219-25. PubMed ID: 18365380
[TBL] [Abstract][Full Text] [Related]
24. Pre-transplant soluble CD30 is associated with bronchiolitis obliterans syndrome after lung transplantation.
Bauwens AM; van de Graaf EA; van Ginkel WG; van Kessel DA; Otten HG
J Heart Lung Transplant; 2006 Apr; 25(4):416-9. PubMed ID: 16563971
[TBL] [Abstract][Full Text] [Related]
25. Association of elevated pretransplant sCD30 levels with graft loss in 206 patients treated with modern immunosuppressive therapies after renal transplantation.
Heinemann FM; Rebmann V; Witzke O; Philipp T; Broelsch CE; Grosse-Wilde H
Transplantation; 2007 Mar; 83(6):706-11. PubMed ID: 17414702
[TBL] [Abstract][Full Text] [Related]
26. Value of soluble CD30 in liver transplantation.
Fábrega E; Unzueta MG; Cobo M; Casafont F; Amado JA; Romero FP
Transplant Proc; 2007 Sep; 39(7):2295-6. PubMed ID: 17889168
[TBL] [Abstract][Full Text] [Related]
27. Soluble CD30 and ELISA-detected human leukocyte antigen antibodies for the prediction of acute rejection in pediatric renal transplant recipients.
Billing H; Sander A; Süsal C; Ovens J; Feneberg R; Höcker B; Vondrak K; Grenda R; Friman S; Milford DV; Lucan M; Opelz G; Tönshoff B
Transpl Int; 2013 Mar; 26(3):331-8. PubMed ID: 23279372
[TBL] [Abstract][Full Text] [Related]
28. Evaluation of soluble CD30 as an immunologic marker in heart transplant recipients.
Spiridon C; Hunt J; Mack M; Rosenthal J; Anderson A; Eichhorn E; Magee M; Dewey T; Currier M; Nikaein A
Transplant Proc; 2006 Dec; 38(10):3689-91. PubMed ID: 17175368
[TBL] [Abstract][Full Text] [Related]
29. Level of soluble CD30 after kidney transplantation correlates with acute rejection episodes.
Yang JL; Hao HJ; Zhang B; Liu YX; Chen S; Na YQ
Transplant Proc; 2008 Dec; 40(10):3381-3. PubMed ID: 19100394
[TBL] [Abstract][Full Text] [Related]
30. Early post-transplant immune monitoring can predict long-term kidney graft survival: soluble CD30 levels, anti-HLA antibodies and IgA-anti-Fab autoantibodies.
Amirzargar MA; Amirzargar A; Basiri A; Hajilooi M; Roshanaei G; Rajabi G; Mohammadiazar S; Solgi G
Hum Immunol; 2014 Jan; 75(1):47-58. PubMed ID: 24055694
[TBL] [Abstract][Full Text] [Related]
31. High variation of individual soluble serum CD30 levels of pre-transplantation patients: sCD30 a feasible marker for prediction of kidney allograft rejection?
Altermann W; Schlaf G; Rothhoff A; Seliger B
Nephrol Dial Transplant; 2007 Oct; 22(10):2795-9. PubMed ID: 17616534
[TBL] [Abstract][Full Text] [Related]
32. Panel reactive HLA antibodies, soluble CD30 levels, and acute rejection six months following renal transplant.
Domingues EM; Matuck T; Graciano ML; Souza E; Rioja S; Falci MC; Monteiro de Carvalho DB; Porto LC
Clin Transplant; 2010; 24(6):821-9. PubMed ID: 20047612
[TBL] [Abstract][Full Text] [Related]
33. Does pretransplant soluble CD30 serum concentration affect deceased-donor kidney graft function 3 years after transplantation?
Kovac J; Arnol M; Vidan-Jeras B; Bren AF; Kandus A
Transplant Proc; 2008 Jun; 40(5):1357-61. PubMed ID: 18589105
[TBL] [Abstract][Full Text] [Related]
34. Association of high post-transplant soluble CD30 serum levels with chronic allograft nephropathy.
Grenzi PC; Campos ÉF; Tedesco-Silva H; Felipe CR; Franco MF; Soares MF; Medina-Pestana JO; Gerbase-Delima M
Transpl Immunol; 2013 Dec; 29(1-4):34-8. PubMed ID: 23928467
[TBL] [Abstract][Full Text] [Related]
35. Relation between pretransplant serum levels of soluble CD30 and acute rejection during the first 6 months after a kidney transplant.
Shooshtarizadeh T; Mohammadali A; Ossareh S; Ataipour Y
Exp Clin Transplant; 2013 Jun; 11(3):229-33. PubMed ID: 23477385
[TBL] [Abstract][Full Text] [Related]
36. Reappraisal of HLA antibody analysis and crossmatching in kidney transplantation.
Lee PC; Ozawa M
Clin Transpl; 2007; ():219-26. PubMed ID: 18642453
[TBL] [Abstract][Full Text] [Related]
37. Hepatocyte growth factor and antibodies to HLA and MICA antigens in heart transplant recipients.
Pavlova YA; Malek I; Honsova E; Netuka I; Sochman J; Lodererova A; Kolesar L; Striz I; Skibova J; Slavcev A
Tissue Antigens; 2010 Nov; 76(5):380-6. PubMed ID: 20604893
[TBL] [Abstract][Full Text] [Related]
38. Soluble CD30 for the prediction and detection of kidney transplant rejection.
Arjona A
Drug News Perspect; 2009 Sep; 22(7):409-13. PubMed ID: 19890498
[TBL] [Abstract][Full Text] [Related]
39. Post-transplant increased levels of serum sCD30 is a marker for prediction of kidney allograft loss in a 5-year prospective study.
Delgado JC; Pavlov IY; Shihab FS
Transpl Immunol; 2009 Dec; 22(1-2):1-4. PubMed ID: 19772921
[TBL] [Abstract][Full Text] [Related]
40. Post-transplant monitoring of soluble CD30 level as predictor of graft outcome: a single center experience from China.
Wang D; Wu W; Yang S; Wang Q; Tan J
Transpl Immunol; 2012 Dec; 27(4):146-50. PubMed ID: 23079227
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
